The long-term goal of the Breast Cancer (BC) Program is to apply this knowledge of biology, genetics and biochemistry of breast cancer towards diagnostic, therapeutic and preventive strategies. To achieve this end, the following Specific Goals will be pursued: 1) To identify aberrant regulatory pathways in breast cancer pathogenesis. Specifically, by analyzing tumor biopsies and model systems, we will dissect the pathways responsible for distinct subtypes of breast cancer and elucidate their mechanistic role in tumor development. 2) To optimize the treatment and prevention of breast cancer. By using tissue, serum and imaging-based biomarkers, we will identify suitable patients for targeted therapy and then measure its efficacy. 3) To improve the quality of breast cancer care. By using novel methodologies to characterize the short and long term risks associated with standard breast cancer treatment, we will conduct clinical trials to evaluate novel interventions to diminish these effects. Since the prior grant period, the number of institution-based clinical trials in breast cancer and the number of patients accrued to therapeutic and supportive care trials has increased, with 5 investigators leading a total of 8 NCI Cooperative Group Trials. The number of new breast cancer cases averaged 437/year;of these, 66 patients/year (peak 76) enrolled on therapeutic clinical trials (15%) and 135 patients/year patients accrued to non-therapeutic interventional trials per year (31%). The majority of these clinical trials were investigator initiated and 48% of patients accrued were minorities. The BC program consists of 28 members (19 full) from eleven departments within the College of Physicians &Surgeons, the Mailman School of Public Health and Biomedical Engineering at Columbia University. The Program is enhanced by large program project grants, including a breast cancer NCI POI focused on signaling pathways in triple negative breast cancer and a DOD Center of Excellence focused on disparities in breast cancer treatment. For the last budget period of the grant (July 1, 2012 - June 30, 2013), the BC Program received a total of $6.48M (direct costs) in cancer-relevant grant support, including $2.48M (direct costs) in NCI funding, $2.84M (direct costs) in other cancer-related peer-reviewed funding, and $1.21M (direct costs) in cancer-related non-peer-reviewed funding. The total number of publications since the previous submission (i.e., 2008-present) was 366, of which 13% were intra-programmatic, 39% inter-programmatic and 21% were in high impact journals (Impact Factor >10).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013696-40
Application #
8753111
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-04
Project End
2019-06-30
Budget Start
2014-07-17
Budget End
2015-06-30
Support Year
40
Fiscal Year
2014
Total Cost
$33,319
Indirect Cost
$12,495
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Mumau, Melanie D; Vanderbeck, Ashley N; Lynch, Elizabeth D et al. (2018) Identification of a Multipotent Progenitor Population in the Spleen That Is Regulated by NR4A1. J Immunol 200:1078-1087
Savage, Thomas M; Shonts, Brittany A; Obradovic, Aleksandar et al. (2018) Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight 3:
Caviglia, Jorge Matias; Yan, Jun; Jang, Myoung-Kuk et al. (2018) MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 67:2414-2429
Jauregui, Ruben; Park, Karen Sophia; Tsang, Stephen H (2018) Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic Genet 39:544-549
Wu, Wen-Hsuan; Tsai, Yi-Ting; Justus, Sally et al. (2018) CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology. Methods Mol Biol 1715:191-205
Yen, Bonnie; Fortson, Katherine T; Rothman, Nyanza J et al. (2018) Clonal Bifurcation of Foxp3 Expression Visualized in Thymocytes and T Cells. Immunohorizons 2:119-128
Ishida, Chiaki T; Zhang, Yiru; Bianchetti, Elena et al. (2018) Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clin Cancer Res 24:5392-5406
Jin, Chun-Hui; Li, Yang; Xia, Jinxing et al. (2018) CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion. Am J Hematol 93:786-793
Renz, Bernhard W; Takahashi, Ryota; Tanaka, Takayuki et al. (2018) ?2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell 33:75-90.e7
Velez, Gabriel; Tang, Peter H; Cabral, Thiago et al. (2018) Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease. Transl Vis Sci Technol 7:12

Showing the most recent 10 out of 331 publications